@celgene.com vaccine Pages on BioPortfolio:

Results from other life science and pharmaceutical sites:

News: The Multiple Myeloma Research Consortium (MMRC) Partners ...
For more information, please visit the Company's website at www.celgene.com. ... MabVax Licenses Cancer Vaccine Technology from Sloan-Kettering ...
http://www.genengnews.com/news/bnitem.aspx?name=40812981&chi...

Thalomid (Thalidomide) capsules: a review of the f...[Drug Saf ...
... Drug Safety Department, Warren, New Jersey 07059, USA. tclark@celgene.com ... 2003]; Surveillance for safety after immunization: Vaccine Adverse Event ...
http://www.ncbi.nlm.nih.gov/pubmed/11235821...

Article : Chiral Chemistry Aids Drug Development Genetic ...
Likewise, Celgene (www.celgene.com) gained approval last May for Focalin XR ... MabVax Licenses Cancer Vaccine Technology from Sloan-Kettering ...
http://www.genengnews.com/articles/chitem.aspx?aid=1103&chid...

The evolution of thalidomide and its IMiD derivatives as ...
... able to enhance a partially effective cancer vaccine and enable the generation ..... Correspondence to: J. Blake Bartlett2 Email: bbartlett@celgene.com ...
http://www.nature.com/nrc/journal/v4/n4/full/nrc1323.html...

Article : Inflammation Research Leads to Targets Genetic ...
1 Oct 2006 ... Celgene (www.celgene.com) is developing five oral drugs for a range of .... MabVax Licenses Cancer Vaccine Technology from Sloan-Kettering ...
http://www.genengnews.com/articles/chitem.aspx?aid=1893&chid...

18 selected items - PubMed Results
... University of Lausanne, Lausanne, Switzerland. vvoelter@celgene.com ... Furthermore, addition of a p38 inhibitor to a pertussis vaccine formulated with ...
http://www.ncbi.nlm.nih.gov/pubmed/18546043,18543038,1854185...

1745-6673-3-S1-S6 1745-6673 Review New drugs targeting Th2 ...
... intravenous dose study in healthy human volunteers ( http://www.celgene.com ). ... A novel approach is represented by an IL-4 peptide-based vaccine for ...
http://www.biomedcentral.com/content/download/xml/1745-6673-...

77 selected items - PubMed Results
... University of Lausanne, Lausanne, Switzerland. vvoelter@celgene.com ..... Both endogenous and vaccine-induced antiganglioside-IgM antibodies appeared to ...
http://www.ncbi.nlm.nih.gov/pubmed/18546261,18500743,1849813...

New drugs targeting Th2 lymphocytes in asthma
... dose study in healthy human volunteers (http://www.celgene.com). ...... Identifying these antigens may aid in IgE/mast cell-dependent vaccine ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=22...

Recent clinical studies of the immunomodulatory drug (IMiD ...
Correspondence to: Dr JB Bartlett, E-mail: bbartlett@celgene.com ..... with whole tumor cell vaccination is mediated by increased Th1-type immunity. ...
http://www.nature.com/bjc/journal/v93/n6/full/6602774a.html...

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright 1997-2008 - BioPortfolio Limited.